FDA Approves Labeling Update for Abbott s HeartMate 3 Heart Pump for use in Pediatric Patients
- Abbott s HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure
- This life-saving technology provides new treatment option for underserved population
News provided by
Share this article
Share this article
ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company s HeartMate 3™ heart pump to be used in pediatric patients with advanced refractory left ventricular heart failure. With the updated labeling, physicians now have additional options for treating this underserved population awaiting a heart transplant or for those not eligible to receive a transplant as a result of potential complications or risk related to the procedure.